Dr. Evan Loh, chief executive officer at Paratek Pharmaceuticals, joins host Roger Waldron on this week's Off the Shelf to discuss the Covid-19 pandemic, the tr...
March 29, 20218:00 am
< a min read
Best listening experience is on Chrome, Firefox or Safari. Subscribe to Off the Shelf’s audio interviews on Apple Podcasts or PodcastOne.
Paratek develops next generation antibiotics to fight antimicrobial resistance with a focus on serious community acquired infections. Loh joined the show to discuss the unspoken pandemic — the troubling rise in antibiotic-resistant infections and the threat to global public health.
Against this backdrop, Loh shared his insights on the market dynamics that create significant challenges for domestic small business firms seeking to develop next generation antibiotics. He also shared Paratek’s story of the development of NUZRA, a fourth-generation tetracycline.
Loh highlighted the fragile market dynamics in creating next generation antibiotics and what can be done to create incentives for future antibiotic development.
Finally, he discussed Paratek’s ongoing work with the Biomedical Advanced Research and Development Authority (BARDA) in delivering its next generation antibiotic to DoD to protect the warfighter.